<DOC>
	<DOCNO>NCT00402818</DOCNO>
	<brief_summary>RESTORE observational , open-label , multi-center , prospective , study enrol Raptiva® ( efalizumab ) treat patient moderate severe chronic plaque psoriasis . The overall duration study approximately 4 year . Patients follow time study enrolment study/treatment termination ; thus active follow-up period vary across subject . Raptiva® ( efalizumab ) treat patient moderate severe chronic plaque psoriasis meeting inclusion/exclusion criterion specify eligible participation study . Objectives : - To document quantify incidence adverse event patient population - To explore association psoriasis treatment change patient outcome , quality life , treatment compliance .</brief_summary>
	<brief_title>RESTORE : Raptiva® ( Efalizumab ) Evaluation Safety Treatment Optimization</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female ≥ 18 year old . Have clinical diagnosis moderate severe chronic plaque psoriasis candidate treatment Raptiva® . Are treated initiate treatment Raptiva® time study enrolment accordance Canadian Product Monograph indication recommendation . Be able provide write informed consent . Agreement participate study , disclose medical event Investigator . The subject must willing able comply protocol requirement duration study . Any contraindication Raptiva® accord Canadian Product Monograph . Any simultaneous participation another clinical evaluation trial psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Moderate severe plaque psoriasis</keyword>
</DOC>